JAZZ PHARMACEUTICALS IRELAND LIMITED

Jazz Pharmaceuticals Ireland Limited is the Irish arm of a global biopharmaceutical company dedicated to delivering life-changing medicines to patients who have limited or no treatment options. By unlocking scientific discoveries and translating them into novel therapies, Jazz aims to give thousands of people worldwide the chance to redefine what's possible in their health journeys.

The company's portfolio focuses on high-unmet-need areas such as HER2-targeted treatments for gastro-oesophageal adenocarcinoma, innovative approaches for treatment-resistant epilepsy, and cutting-edge therapies for rare cancers. Recent milestones include the launch of Ziihera® (zanidatamab-hrii) in combination regimens, which has demonstrated unprecedented median overall survival benefits, and ongoing clinical trials that continue to expand therapeutic options. Through patient-focused stories, research collaborations and a commitment to scientific innovation, Jazz Pharmaceuticals Ireland works to improve outcomes and support patients, caregivers and the broader medical community.